Munich - Delayed Quote EUR

Q32 Bio Inc. R (DB0.MU)

3.1800

+0.1200

(+3.92%)

At close: December 20 at 8:13:48 AM GMT+1

Q32 Bio price target lowered to $20 from $80 at Oppenheimer

Oppenheimer lowered the firm’s price target on Q32 Bio (QTTB) to $20 from $80 and keeps an Outperform rating on the shares. The firm notes Q32 Bio reported negative AD but positive AA results along with an update on clinical development plans for bempikibart. While Oppenheimer is clearly disappointed by bempi’s failure to advance in AD, it also thinks the AA opportunity remains underappreciated, with a potentially differentiated MoA in a highly underserved disease dominated by JAK inhibitors. Pu

TipRanks 8 days ago

QTTB
Investors Slaughter Q32 Bio On A 'Messy' Update In Eczema, Alopecia Treatment

Q32 Bio delivered a "messy" update for its eczema and alopecia treatment, leading the biotech stock to collapse to a record low.

Investor's Business Daily 9 days ago

QTTB
Q32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata Development Program

Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced topline results from the SIGNAL-AA Phase 2a signal finding clinical trial evaluating bempikibart (ADX-914), which identified encouraging clinical activity in patients with alopecia areata (AA). The Company plans to expand the SIGNAL-AA Phase 2a clinical trial and enroll additional patients evaluating bempikibart in AA.

PR Newswire 10 days ago

QTTB
Q32 Bio Inc.'s (NASDAQ:QTTB) largest shareholders are private equity firms with 51% ownership, institutions own 30%

Key Insights Significant control over Q32 Bio by private equity firms implies that the general public has more power to...

Simply Wall St. 16 days ago

QTTB
Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today reported financial results for the quarter ended September 30, 2024, and provided recent corporate updates.

PR Newswire last month

QTTB
Q32 Bio to Participate in Guggenheim's Inaugural Healthcare Innovation Conference

Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced that management will participate in a fireside chat at 10:00 a.m. E.T. on Tuesday, November 12, 2024 at Guggenheim's Inaugural Healthcare Innovation Conference in Boston, MA.

PR Newswire last month

QTTB
Q32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024

Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced that it will present clinical data supporting its program for innate immunity, ADX-097, at the American Society of Nephrology (ASN) Kidney Week 2024, taking place October 24-27, 2024, in San Diego, Calif. Abstracts are available here. ADX-097, Q32 Bio's lead product candidate from its tissue-targeted complement inhibitor platfo

PR Newswire 2 months ago

QTTB
Q32 Bio to Participate in Upcoming September Investor Conferences

Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced that management will participate in three upcoming investor conferences in September:

PR Newswire 3 months ago

QTTB
Q32 Bio Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart for Atopic Dermatitis

Q32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced that it has completed enrollment in the SIGNAL-AD Phase 2 clinical trial of bempikibart (ADX-914) for the treatment of persistent, moderate-to-severe atopic dermatitis (AD). Bempikibart is a fully human anti-IL-7Rα antibody that is designed to re-regulate adaptive immune function by blocking IL-7 and TSLP signaling, both of whi

PR Newswire 5 months ago

QTTB
Q32 Bio Joins Russell 3000® Index

Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced that the company is joining the broad-market Russell 3000® Index at the conclusion of the 2024 Russell Indexes annual reconstitution, effective upon the U.S. market opening today, July 1, 2024.

PR Newswire 5 months ago

QTTB
Q32 Bio Inc.'s (NASDAQ:QTTB) last week's 15% decline must have disappointed private equity firms who have a significant stake

Key Insights Q32 Bio's significant private equity firms ownership suggests that the key decisions are influenced by...

Simply Wall St. 5 months ago

QTTB
Q32 Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

Q32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today reported financial results for the quarter ended March 31, 2024 and provided recent corporate updates.

PR Newswire 7 months ago

QTTB
Q32 Bio Appoints Lee Kalowski as President & Chief Financial Officer

Q32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced the appointment of Lee Kalowski as President and Chief Financial Officer. Mr. Kalowski brings over 20 years of biopharmaceutical experience with a focus on strategy, raising capital, and financial operations.

PR Newswire 8 months ago

QTTB

Performance Overview

Return	DB0.MU	S&P 500
YTD	-83.78%	+24.34%
1-Year	-83.78%	+24.38%
3-Year	-83.78%	+28.36%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Q32 Bio Inc. R (DB0.MU)

Q32 Bio price target lowered to $20 from $80 at Oppenheimer

Investors Slaughter Q32 Bio On A 'Messy' Update In Eczema, Alopecia Treatment

Q32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata Development Program

Q32 Bio Inc.'s (NASDAQ:QTTB) largest shareholders are private equity firms with 51% ownership, institutions own 30%

Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Q32 Bio to Participate in Guggenheim's Inaugural Healthcare Innovation Conference

Q32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024

Q32 Bio to Participate in Upcoming September Investor Conferences

Q32 Bio Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart for Atopic Dermatitis

Q32 Bio Joins Russell 3000® Index

Q32 Bio Inc.'s (NASDAQ:QTTB) last week's 15% decline must have disappointed private equity firms who have a significant stake

Q32 Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

Q32 Bio Appoints Lee Kalowski as President & Chief Financial Officer

Performance Overview